UK
Therapeutic Areas
Ocugen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OCU400 (AAV5-hNR2E3) | Retinitis Pigmentosa | Phase 3 |
| OCU410ST (AAV5-hRORA) | Stargardt Disease | Phase 2/3 |
| OCU410 (AAV5-hRORA) | Dry Age-Related Macular Degeneration (Geographic Atrophy) | Phase 2 |
| OCU200 (Transferrin-Tumstatin) | Diabetic Macular Edema, Diabetic Retinopathy, Wet AMD | Phase 1 |
| OCU500 | Inhaled Vaccine for COVID-19 Prevention | IND Cleared |
| OCU510 | Quadrivalent Inhaled Vaccine for Flu Prevention | IND Planned |
| OCU520 | Combination Quadrivalent Flu & COVID-19 Inhaled Vaccine | IND Planned |
Leadership Team at Ocugen
SM
Shankar Musunuri
Chairman, CEO and Co-founder
RJ
Rita Johnson-Greene
Chief Financial Officer
AU
Arun Upadhyay
Chief Scientific Officer, Head of Research & Development and Medical
AG
Abhi Gupta
Executive Vice President, Commercial and Business Development
KC
Kristen Craft
Head of People and Culture
TM
Thais McNeal
Senior Director Government & Industry Affairs, Head Patient Advocacy & Alliance Development
SK
Sree Kattala
Research Associate Scientist